NCT01863784View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Hepatic Impairment

Interventions

DRUG

JNJ-38518168

All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.

Trial Locations (3)

Unknown

Orlando

Knoxville

San Antonio

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT01863784 - A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function | Biotech Hunter | Biotech Hunter